• Citer

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

par Saglio, G;Kim, Sung-Soo ;Issaragrisil, Surapol;le Coutre, Philipp;Etienne, Gabriel;Lobo, Clarisse;Pasquini, Ricardo;Clark, Richard E;Hochhaus, A.;Hughes, T P;Gallagher, Neil;Hoenekopp, Albert;Dong, Mei;Haque, A;Larson, RA;Kantarjian, Hagop M;ENESTnd Investigators,
Référence The New England journal of medicine, 362, 24, page (2251-2259)
Publication Publié, 2010-06

Article révisé par les pairs

• Détails
• Contenu

Titre:	Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Auteur:	Saglio, G; Kim, Sung-Soo; Issaragrisil, Surapol; le Coutre, Philipp; Etienne, Gabriel; Lobo, Clarisse; Pasquini, Ricardo; Clark, Richard E; Hochhaus, A.; Hughes, T P; Gallagher, Neil; Hoenekopp, Albert; Dong, Mei; Haque, A; Larson, RA; Kantarjian, Hagop M; ENESTnd Investigators,
Informations sur la publication:	The New England journal of medicine, 362, 24, page (2251-2259)
Statut de publication:	Publié, 2010-06
Sujet CREF:	Cancérologie
MeSH keywords:	Adolescent
	Adult
	Aged
	Aged, 80 and over
	Antineoplastic Agents -- administration & dosage -- adverse effects -- therapeutic use
	Blast Crisis -- prevention & control
	Disease Progression
	Female
	Fusion Proteins, bcr-abl -- antagonists & inhibitors
	Humans
	Kaplan-Meier Estimate
	Leukemia, Myeloid, Chronic-Phase -- drug therapy -- pathology
	Male
	Middle Aged
	Piperazines -- adverse effects -- therapeutic use
	Protein Kinase Inhibitors -- administration & dosage -- adverse effects -- therapeutic use
	Pyrimidines -- administration & dosage -- adverse effects -- therapeutic use
	Young Adult
Note générale:	Clinical Trial, Phase III
	Comparative Study
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0028-4793
	info:doi/10.1056/NEJMoa0912614
	info:pii/NEJMoa0912614
	info:pmid/20525993